About
Science
- PAM Pathway
- Publications
Pipeline
Clinical Trials
Investors
Careers

Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models

Post navigation

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Search for:

Recent Posts

Developing first-in-class therapeutics using a 3rd generation diagnostic platform

Recent Comments

Archives

October 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

16305 36th Avenue North
Minneapolis, MN 55446

Follow us on

in x

©2025 Celcuity Inc.

Privacy Policy Accessibility Statement